US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

IMUX

Immunic (IMUX)

Immunic Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IMUX

1 2 3 4 5 6 7 8 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
03/03/2025	05:30	PR Newswire (US)	Immunic to Participate in Scientific and Investor Conferences in March	NASDAQ:IMUX	Immunic Inc
26/02/2025	05:30	PR Newswire (US)	Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis	NASDAQ:IMUX	Immunic Inc
20/02/2025	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMUX	Immunic Inc
20/02/2025	06:30	PR Newswire (US)	Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing	NASDAQ:IMUX	Immunic Inc
14/02/2025	09:16	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:IMUX	Immunic Inc
04/02/2025	05:30	PR Newswire (US)	Immunic to Participate in Investor and Scientific Conferences in February	NASDAQ:IMUX	Immunic Inc
07/01/2025	05:30	PR Newswire (US)	Immunic Highlights 2024 Accomplishments and Upcoming Milestones	NASDAQ:IMUX	Immunic Inc
09/12/2024	07:30	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:IMUX	Immunic Inc
06/12/2024	16:32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMUX	Immunic Inc
26/11/2024	05:30	PR Newswire (US)	Immunic, Inc. to Participate in Investor Conference in December	NASDAQ:IMUX	Immunic Inc
14/11/2024	16:33	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:IMUX	Immunic Inc
13/11/2024	05:30	PR Newswire (US)	Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology	NASDAQ:IMUX	Immunic Inc
12/11/2024	08:31	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:IMUX	Immunic Inc
07/11/2024	06:04	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IMUX	Immunic Inc
07/11/2024	05:30	PR Newswire (US)	Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:IMUX	Immunic Inc
31/10/2024	05:30	PR Newswire (US)	Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update	NASDAQ:IMUX	Immunic Inc
29/10/2024	05:30	PR Newswire (US)	Immunic to Participate in Industry, Scientific and Investor Conferences in November	NASDAQ:IMUX	Immunic Inc
22/10/2024	05:30	PR Newswire (US)	Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis	NASDAQ:IMUX	Immunic Inc
18/09/2024	05:30	PR Newswire (US)	Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis	NASDAQ:IMUX	Immunic Inc
04/09/2024	05:30	PR Newswire (US)	Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome	NASDAQ:IMUX	Immunic Inc
28/08/2024	05:30	PR Newswire (US)	Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September	NASDAQ:IMUX	Immunic Inc
08/08/2024	05:30	PR Newswire (US)	Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:IMUX	Immunic Inc
01/08/2024	05:30	PR Newswire (US)	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update	NASDAQ:IMUX	Immunic Inc
24/07/2024	15:10	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IMUX	Immunic Inc
24/07/2024	05:30	PR Newswire (US)	Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec	NASDAQ:IMUX	Immunic Inc
09/07/2024	05:30	PR Newswire (US)	Immunic Appoints Jason Tardio as Chief Operating Officer and President	NASDAQ:IMUX	Immunic Inc
10/06/2024	15:05	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IMUX	Immunic Inc
02/06/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:IMUX	Immunic Inc
28/05/2024	05:30	PR Newswire (US)	Immunic to Participate in Industry and Scientific Conferences in June	NASDAQ:IMUX	Immunic Inc
24/05/2024	15:06	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:IMUX	Immunic Inc

Showing the most relevant articles for your search:NASDAQ:IMUX

1 2 3 4 5 6 7 8 Próxima >

Sangoma Technologies

Century Global Commodities

Alpha Financial Markets ...

Dermasalve Sciences

JPMorgan CDR CAD Hedged

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones